Prodigiosin Release from an Implantable Biomedical Device: Effect on Cell Viability

Abstract

This paper present the results of (experiments and models) biosynthesized prodigiosin (PG) released from an implantable biomedical device on the viability of cancer cells. The implantable biomedical devices were obtained from poly-di-methyl-siloxane (PDMS) packages with well-controlled micro-channels and drug storage compartments, along with a drug storing polymer core (which contains thermosensitive Poly (N-isopropylacrylamide)(PNIPA)-based gels). The results were compared with drugs elution from devices loaded with paclitaxel TM . The effects of localized release of PG and paclitaxel (PTx) on cell viability were elucidated via clonogenic assay testing on MDA-MB-231 breast cancer cell line. The effects of PG and PTx released were also tested over a range of temperatures (37-45 ̊C) in which localized hyperthermia is applicable. The trends in the results were analysed using statistical models before discussion their implications for localized treatment of breast cancer.